Greenwich LifeSciences (GLSI) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 37.0% versus a loss of 4.1%. Greenwich LifeSciences is the larger company by market cap ($219.9 million vs $208.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | TRDA |
|---|---|---|
| Share price | $14.98 | $5.35 |
| Market cap | $219.88M | $208.31M |
| 1-day change | -2.66% | -4.63% |
| YTD return | -26.75% | -45.43% |
| 1-year return | +37.04% | -4.10% |
| 5-year return | -59.46% | — |
| EPS (TTM) | $-1.53 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $16.45 |
| 52-week low | $7.78 | $5.15 |
| Distance from 52-week high | -56.07% | -67.48% |
| Analyst consensus | none | none |
| Avg. price target upside | +280.51% | +255.14% |
| Average volume | 138.72K | 359.01K |
| Shares outstanding | 14.68M | 38.94M |
| Employees | — | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed TRDA by 41.1 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
GLSI vs TRDA FAQ
Which is bigger, Greenwich LifeSciences or Entrada Therapeutics?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $219.88M compared with $208.31M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, GLSI or TRDA?
GLSI returned +37.04% over the past 12 months, compared with -4.10% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.